BR112023001060A2 - Composto, composição farmacêutica, combinação, processo para fabricar uma composição farmacêutica, e, método de tratamento e/ou prevenção de um transtorno - Google Patents
Composto, composição farmacêutica, combinação, processo para fabricar uma composição farmacêutica, e, método de tratamento e/ou prevenção de um transtornoInfo
- Publication number
- BR112023001060A2 BR112023001060A2 BR112023001060A BR112023001060A BR112023001060A2 BR 112023001060 A2 BR112023001060 A2 BR 112023001060A2 BR 112023001060 A BR112023001060 A BR 112023001060A BR 112023001060 A BR112023001060 A BR 112023001060A BR 112023001060 A2 BR112023001060 A2 BR 112023001060A2
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical composition
- combination
- compounds
- disorder
- prevention
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 8
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 5
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 230000003281 allosteric effect Effects 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000002207 metabolite Substances 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- LDIJKUBTLZTFRG-UHFFFAOYSA-N pyrazolo[1,5-a]pyrimidine Chemical class N1=CC=CN2N=CC=C21 LDIJKUBTLZTFRG-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Abstract
COMPOSTO, COMPOSIÇÃO FARMACÊUTICA, COMBINAÇÃO, PROCESSO PARA FABRICAR UMA COMPOSIÇÃO FARMACÊUTICA, E, MÉTODO DE TRATAMENTO E/OU PREVENÇÃO DE UM TRANSTORNO. A invenção refere-se a novos derivados de pirazolo[1,5- a]pirimidina de fórmula (I) ou sais farmaceuticamente aceitáveis, metabólitos biologicamente ativos, pró-fármacos, racematos, enantiômeros, diastereoisômeros, solvatos e hidratos do mesmo que servem como moduladores alostéricos positivos de receptores GABAB. A invenção também se refere ao processo para produzir tais compostos e intermediários essenciais usados no processo. A invenção refere-se adicionalmente a composições farmacêuticas compreendendo tais compostos, opcionalmente em combinação com dois ou mais agentes terapêuticos diferentes e ao uso de tais compostos em métodos para tratar doenças e condições mediadas e moduladas pelo mecanismo alostérico positivo de receptores GABAB. A invenção também provê um método para fabricar medicamentos úteis no tratamento de tais transtornos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HUP2000254 | 2020-08-05 | ||
| PCT/IB2021/057180 WO2022029666A1 (en) | 2020-08-05 | 2021-08-05 | PHARMACOLOGICALLY ACTIVE HETEROCYCLIC-SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023001060A2 true BR112023001060A2 (pt) | 2023-03-07 |
Family
ID=89662993
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023001060A BR112023001060A2 (pt) | 2020-08-05 | 2021-08-05 | Composto, composição farmacêutica, combinação, processo para fabricar uma composição farmacêutica, e, método de tratamento e/ou prevenção de um transtorno |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20230286988A1 (pt) |
| EP (1) | EP4192833A1 (pt) |
| JP (1) | JP2023536197A (pt) |
| KR (1) | KR20230049677A (pt) |
| CN (1) | CN116075514A (pt) |
| AR (1) | AR123154A1 (pt) |
| AU (1) | AU2021319420A1 (pt) |
| BR (1) | BR112023001060A2 (pt) |
| CA (1) | CA3185566A1 (pt) |
| CL (1) | CL2023000352A1 (pt) |
| CO (1) | CO2023001367A2 (pt) |
| IL (1) | IL300208A (pt) |
| MX (1) | MX2023001444A (pt) |
| PE (1) | PE20240107A1 (pt) |
| TW (1) | TW202220992A (pt) |
| WO (1) | WO2022029666A1 (pt) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116077459B (zh) * | 2023-04-10 | 2023-07-07 | 上海赛默罗生物科技有限公司 | α5-GABAA受体调节剂的胶囊剂及其制备方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ID29065A (id) | 1998-12-18 | 2001-07-26 | Schering Corp | Penghambat-penghambat farnesil protein transferase |
| WO2005094828A1 (en) | 2004-03-02 | 2005-10-13 | F. Hoffmann-La Roche Ag | 4- (sulfanyl-pyrimidin-4-ylmethyl) -morpholine derivatives and related compounds as gaba receptor ligands for the treatment of anxiety, depression and epilepsy |
| GB0512844D0 (en) | 2005-06-23 | 2005-08-03 | Novartis Ag | Organic compounds |
| WO2008024371A2 (en) | 2006-08-21 | 2008-02-28 | Prexa Pharmaceuticals, Inc. | Multimediator transporter inhibitors for use in treatment of central nervous system disorders |
| US20120157433A1 (en) | 2009-09-04 | 2012-06-21 | Pfister Keith B | Heteroaryl Compounds as Kinase Inhibitors |
| TWI648281B (zh) | 2013-10-17 | 2019-01-21 | 日商安斯泰來製藥股份有限公司 | 含硫二環式化合物 |
| ES2902806T3 (es) | 2014-04-23 | 2022-03-29 | Dart Neuroscience Llc | Composiciones que contienen compuestos de [1,2,4]triazolo[1,5-a]pirimidin-7-ilo sustituidos como inhibidores de PDE2 |
| SI3149001T1 (sl) * | 2014-05-28 | 2019-08-30 | Novartis Ag | Novi derivati pirazolo pirimidina in njihova uporaba kot inhimitorji malt1 |
| EP3286192A1 (en) | 2015-04-20 | 2018-02-28 | AbbVie Deutschland GmbH & Co KG | Substituted pyrazolopyrimidines and method of use |
| JP2018199623A (ja) | 2015-10-22 | 2018-12-20 | 大正製薬株式会社 | 含窒素縮合複素環化合物 |
| HU231058B1 (hu) * | 2017-03-13 | 2020-04-28 | Richter Gedeon Nyrt. | Gyógyászatilag hatékony aliciklusos-szubsztituált pirazolo[1,5-a]pirimidin származékok |
| HU231057B1 (hu) | 2017-03-13 | 2020-04-28 | Richter Gedeon Nyrt | Gyógyászatilag hatékony aril-szubsztituált pirazolo[1,5-a]pirimidin származékok |
| HU231150B1 (hu) | 2017-03-13 | 2021-03-29 | Richter Gedeon Nyrt | Eljárás racém 3-alkilpiperidin-3-karbonsav-etil-észterek optikai izomerjeinek elválasztására |
-
2021
- 2021-08-02 TW TW110128314A patent/TW202220992A/zh unknown
- 2021-08-05 JP JP2023507435A patent/JP2023536197A/ja active Pending
- 2021-08-05 MX MX2023001444A patent/MX2023001444A/es unknown
- 2021-08-05 PE PE2023000205A patent/PE20240107A1/es unknown
- 2021-08-05 KR KR1020237007966A patent/KR20230049677A/ko unknown
- 2021-08-05 IL IL300208A patent/IL300208A/en unknown
- 2021-08-05 CN CN202180058179.4A patent/CN116075514A/zh active Pending
- 2021-08-05 WO PCT/IB2021/057180 patent/WO2022029666A1/en active Application Filing
- 2021-08-05 AU AU2021319420A patent/AU2021319420A1/en active Pending
- 2021-08-05 CA CA3185566A patent/CA3185566A1/en active Pending
- 2021-08-05 AR ARP210102183A patent/AR123154A1/es unknown
- 2021-08-05 US US18/040,456 patent/US20230286988A1/en active Pending
- 2021-08-05 BR BR112023001060A patent/BR112023001060A2/pt unknown
- 2021-08-05 EP EP21755582.0A patent/EP4192833A1/en active Pending
-
2023
- 2023-02-03 CL CL2023000352A patent/CL2023000352A1/es unknown
- 2023-02-08 CO CONC2023/0001367A patent/CO2023001367A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2023001444A (es) | 2023-03-08 |
| CN116075514A (zh) | 2023-05-05 |
| PE20240107A1 (es) | 2024-01-22 |
| KR20230049677A (ko) | 2023-04-13 |
| WO2022029666A1 (en) | 2022-02-10 |
| AU2021319420A8 (en) | 2023-03-30 |
| JP2023536197A (ja) | 2023-08-23 |
| CO2023001367A2 (es) | 2023-02-16 |
| AR123154A1 (es) | 2022-11-02 |
| US20230286988A1 (en) | 2023-09-14 |
| EP4192833A1 (en) | 2023-06-14 |
| AU2021319420A1 (en) | 2023-03-16 |
| CA3185566A1 (en) | 2022-02-10 |
| CL2023000352A1 (es) | 2023-09-01 |
| IL300208A (en) | 2023-03-01 |
| TW202220992A (zh) | 2022-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK0665843T3 (da) | Substituerede quinuclidiner som substans P-antagonister | |
| MA51828B1 (fr) | Macrocycles utilisés en tant que modulateurs du régulateur de la conductance transmembranaire de fibrose kystique, compositions pharmaceutiques de ceux-ci, leur utilisation dans le traitement de la fibrose kystique et procédé de fabrication associé | |
| MA46357B1 (fr) | Modulateur de régulateur de conductance transmembranaire de fibrose kystique, compositions pharmaceutiques, procédés de traitement et procédé de fabrication du modulateur | |
| PH12019501968A1 (en) | PHARMACOLOGICALLY ACTIVE ALICYCLIC-SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES | |
| BRPI0614168A2 (pt) | Composto ou um sal, hidrato, solvato, isoforma, tautômero, isômero óptico farmaceuticamente aceitável ou uma combinação dos mesmos, composição farmacêutica, método para o tratamento ou prevenção de distúrbios neurológicos e psquiátricos, uso de um composto, e, processo para a preparação de um composto | |
| EA200500018A1 (ru) | Бензконденсированные гетероариламидные производные тиенопиридинов, применяемые в качестве терапевтических агентов, фармацевтические композиции, включающие их, и способы их применения | |
| UA86617C2 (en) | 2-(1-AZA-BICYCLO[2.2.2]OCT-3-YL)-2,3-DIHYDROISOINDOL-l-ONE/5,6-DIHYDRO-FURO[2,3-c]PYRROL-4-ONE DERIVATIVES AS LIGANDS FOR ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR | |
| NO20091938L (no) | 7,8-dihydro-1,6-naftyridin-5(6H)-oner og relaterte bicykliske forbindelser som inhibitorer av dipeptidyl-peptidaser IV og metoder | |
| MX2022000244A (es) | Pirrolo[2,3-b]pirazinas como inhibidores de hpk1 y uso de las mismas. | |
| UY28135A1 (es) | Derivados de pirimidina para el tratamiento de crecimiento celular anormal | |
| BRPI0507786A (pt) | composto e sais farmaceuticamente aceitáveis do mesmo, formulação farmacêutica, uso de um composto, método de tratar uma doença, e, processo para a preparação de compostos | |
| HK1120725A1 (en) | Tetrahydro-beta-carbolin-sulfonamide derivatives as 5-ht6ligands | |
| BR112023001060A2 (pt) | Composto, composição farmacêutica, combinação, processo para fabricar uma composição farmacêutica, e, método de tratamento e/ou prevenção de um transtorno | |
| PH12020500548A1 (en) | Triazolobenzazepines as vasopressin v1a receptor antagonists | |
| MX2022015554A (es) | Moduladores de molecula peque?a de interleucina 17 (il-17). | |
| AR001931A1 (es) | Compuesto de 7-acilamino-3-iminometil (sustituido)cefalosporinas un proceso para su producción intermediarios en su producción una composición farmacéutica que contiene tales compuestos su utilizacióncomo compuestos farmacéuticos y un método para tratar enfermedades microbianas mediante administración de tales compuestos | |
| EA202190857A1 (ru) | Бициклические производные как модуляторы 5 рецепторов gabaa | |
| MX2021013576A (es) | Compuesto utilizado como inhibidor de la quinasa y aplicación del mismo. | |
| MX2023006751A (es) | Nuevo derivado de camptotecina, composicion que comprende el mismo y su uso. | |
| MX2022011354A (es) | Compuestos de pirimidina fusionados como moduladores de kcc2. | |
| MX2023003576A (es) | Compuesto como inhibidor de la akt cinasa. | |
| MX2023004297A (es) | Derivados de 2-oxo-dihidroquinolin-3-carboxamida como moduladores del receptor gaba tipo a. | |
| CA3156074A1 (en) | MLL1 INHIBITORS AND ANTICANCER AGENTS | |
| CO2024005424A2 (es) | Derivados de amina bicíclicos como moduladores de receptor gabaa α5 | |
| ECSP23073082A (es) | Nuevos moduladores alostéricos negativos ciclopenta[c]pirrol de NR2B |